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Accepted 18 October 2011AbstractObjective: A recent breakthrough demonstrated that ectopic expression of four genes is sufficient to reprogram human fibroblasts into inducible
pluripotent stem cells (iPSCs). However, it remains unknown whether human endometrial fibroblasts (EMFs) are capable of being reprog-
rammed into EMF-derived iPSCs (EMF-iPSCs).
Methods: EMFs were obtained from donors in their third and fourth decade of life and were reprogrammed into iPSCs using retroviral
transduction with Oct-4, Sox2, Klf4, and c-Myc.
Results: The EMF-iPSCs displayed the accelerated expression of endogenous Nanog and OCT-4 during reprogramming compared with EMFs.
As a result, EMF-iPSC colonies that could be subcultured and propagated were established as early as 12 days after transduction. After 2 weeks
of reprogramming, the human endometrial cells yielded significantly higher numbers of iPSC colonies and formed more 3D spheroid bodies than
the EMFs. We have shown that human EMF-iPSCs are able to differentiate into neuronal-like cells, adipocytes, and osteocyte-like cells that
express specific osteogenic genes.
Conclusion: Human EMFs can undergo reprogramming to establish pluripotent stem cell lines in female donors by the retroviral transduction of
Oct-4, Sox2, Klf4, and c-Myc.
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Stem cells are considered a promising resource for
restorative cell therapy for the treatment of various diseases in
a wide range of clinical areas. Recent technical advances have
demonstrated that induced pluripotent stem cells (iPSCs) can
be generated from mouse embryonic fibroblasts (MEFs) and
from human fibroblasts using retroviral transfection of the
following four transcription factors: Oct-4, Sox2, c-Myc, andcs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Clinical characteristics of patients.
Normal endometrial
tissue
Age Phase Isolation of
EMFs
Reprogramming
EMF-iPSCs
Case 1 37 Proliferative Successful Successful
Case 2 40 Secretory Successful Successful
Case 3 41 Proliferative Successful Successful
EMF ¼ Endometrial fibroblasts; EMF-iPSCs ¼ Endometrial inducible
pluripotent stem cells.
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numerous properties similar to those of embryonic stem cells
(ESCs). iPSCs share the same morphological features as ESCs
as well as the abilities of self-renewal and differentiation into
three germ layers [1]. They are indistinguishable from ESCs
in morphology, proliferative abilities, surface antigens, gene
expression, epigenetic status of pluripotent cell-specific
genes, and telomerase activity [1]. Several molecular and
functional assays are able to evaluate the similarities between
iPSCs and ESCs. These similarities include the reactivation of
genes associated with self-renewal and pluripotency; telo-
merase activity; X chromosome and stage-specific embryonic
surface antigens; suppression of somatic genes associated
with the cell of origin; silencing of exogenous factors; capa-
bilities of in vitro differentiation; demethylation of promoters
of pluripotency genes; and in vivo teratoma formation,
chimera contribution, germline transmission, and tetraploid
complementation [5e7]. Other advantages of iPSCs over
ESCs include the ability of iPSCs to be derived from the
patient’s somatic cells, which avoids the potential for immune
rejection and the absence of the ethical concerns associated
with ESCs. For example, a recent study demonstrated that
patient-specific iPSCs derived from dermal fibroblasts of
patients with long-QT syndrome can differentiate into func-
tional cardiac myocytes but recapitulated the electrophysio-
logical features of the disorder [8]. Safe induced pluripotent
stem clone-derived neural stem cell/neural progenitor cells
(NPCs) could be an important source for transplantation
therapy in stroke and neurodegenerative diseases [9]. The use
of L-Myc to replace c-Myc, combined with Oct-4/Sox2/Klf4,
promotes iPSC generation without tumor formation [10]. We
previously showed subdural transplantation of iPSCs mixed
with fibrin glue did not result in tumor formation after 6
weeks [11]. Therefore, the major advantages of iPSCs over
ESCs are that iPSCs can be derived from a patient’s own
somatic cells, can be used for autologous transplantation
without the risk of rejection, avoid the ethical concerns raised
by using ESCs, and are considered candidates for cell therapy
[1e4].
The human endometrium is responsive to sex steroid
hormones and undergoes extraordinary growth in a cyclic
manner. The endometrium is shed and regenerated throughout
a woman’s lifetime. It has been proposed that the human
endometrium might contain a population of stem cells that is
responsible for its remarkable ability to regenerate [12,13].
Recently, endometrial-derived stem cells from human endo-
metrium were isolated and demonstrated the potential of
multipotent capacity to differentiate into different-lineage cells
[14,15]. However, the multipotent capacity of the endometrial-
derived stem cells of iPSCs should be investigated and further
compared with pluripotent stem cells and/or ESCs. More
recently, Park et al. [16] showed that human endometrium
cells express elevated levels of pluripotent factors, which, with
additionally defined factors, result in significantly more effi-
cient and accelerated generation of iPSCs compared with
conventional somatic cells [16]. However, whether endome-
trial fibroblasts (EMFs) can be efficiently reprogrammed intoiPSC- or ESC-like cells and possess the pluripotent function of
EMF-derived iPSCs (EMF-iPSCs) to differentiate into
multiple-lineage cells remains unknown. In this study, we
exploited the remarkable capacity of human EMFs to undergo
reprogramming to establish pluripotent stem cell lines in
female donors by the retroviral transduction of Oct-4, Sox2,
Klf4, and c-Myc (Table 1).
Materials and methodsTissue collectionEndometrial tissue samples were obtained from women
with uterine fibroids who had not undergone hormone therapy
(n ¼ 3, aged 37e41 years; menstrual cycle phase: two
proliferative phase and one mid-secretory phase). Samples
were scraped from the hysterectomy specimens with a curette.
The phase of the menstrual cycle was assessed by endometrial
histology. This study followed the tenets of the Declaration of
Helsinki and was approved by the Institutional Review Board
of Taipei Veterans General Hospital, Taiwan. In addition, pre-
operative written informed consent was obtained from each
patient (Table 1).Isolation of EMFsEMFs were derived directly from the patients’ endometria.
The endometrial biopsy was rapidly washed in Ca2þ/Mg2þ-
free phosphate-buffered saline (PBS) in a Petri dish, cut into
small fragments, and transferred to a flask [17]. The endo-
metrial tissue was then digested by collagenase P (Roche,
Mannheim, Germany) in HEPES-buffered saline for 7 h at
37C. These cells were plated in a 6-cm tissue culture dish.
The expansion medium consisted of Dulbecco’s Modified
Eagle’s Medium (DMEM)-low glucose (LG) (Gibco, Grand
Island, NY, USA) and 10% fetal bovine serum (FBS; Gibco)
supplemented with 10 ng/mL basic fibroblast growth factor, 10
ng/ml epidermal growth factor, 10 ng/mL platelet-derived
growth factor-BB (R&D Systems, Minneapolis, Minnesota,
USA), 100 units/mL penicillin, 1000 mg/mL streptomycin, and
2 mM L-glutamine (Gibco).Induction of iPSCsiPSCs generated from the EMFs were reprogrammed by the
transduction of retroviral vectors encoding Oct-4, Sox2, Klf4,
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procedures of iPSC reprogramming and culture methods are
described below.iPSCs culture, in vitro passage, expansion, storage, and
differentiationHuman iPSCs were generated from human endometrial
fibroblast derived from healthy donors. The iPSCs were
reprogrammed by the transduction of retroviral vectors
encoding four transcription factors (Oct-4, Sox2, Klf4, and
c-Myc), as described previously, with some modifications
[1,16,18,19]. Briefly, undifferentiated iPSCs were routinely
cultured and expanded on mitotically inactivated EMFs
(50,000 cells/cm2) in six-well culture plates (BD tech-
nology, Franklin Lakes, NJ, USA) in the presence of 0.3%
leukemia inhibitory factor in an iPSC medium consisting of
DMEM (Sigma, St Louis, MO, USA) supplemented with
15% FBS (Invitrogen, Carlsbad, CA), 100 mM minimal
essential medium nonessential amino acids (Sigma),
0.55 mM 2-mercaptoethanol (Gibco), and antibiotics (Invi-
trogen). These iPSCs were transfected with pCX-EGFP to
constitutively express green fluorescence and were main-
tained and differentiated in vitro, as described previously
[20]. Every 3e4 days, colonies were detached with 0.2%
collagenase IV (Invitrogen), dissociated into single cells
with 0.025% trypsin (Sigma-Aldrich, St. Louis, MO, USA)
and 0.1% chicken serum (Invitrogen) in PBS and replated
onto MEFs.Induced differentiation of EMF-iPSCs into adipogenic,
chondrogenic, and neuronal cells
Adipogenic differentiation
First, 1  105 EMF-iPSCs at the fifth to eighth passage
were treated with adipogenic medium for 14 days. Adipogenic
medium consisted of Iscove’s modified Dulbecco’s medium
(IMDM) supplemented with 0.5 mmol/L 3-isobutyl-1-
methylxanthine (Sigma-Aldrich), 1 mmol/L hydrocortisone
(Sigma-Aldrich), 0.1 mmol/L indomethacin (Sigma-Aldrich),
and 10% rabbit serum (Sigma-Aldrich). For the evaluation of
adipocytes, cells were fixed with 4% formaldehyde and
stained with Oil-red O (Sigma) [13].
Osteogenic differentiation
The 1  105 EMF-iPSCs at the fifth to eighth passage were
treated with osteogenic medium for 3 weeks. Osteogenic
medium consisted of DMEM-LG (Gibco) supplemented with
50 lg/mL ascorbate-2 phosphate, 10-8 M dexamethasone, and
10 mM b-glycerophosphate (all from Sigma). Osteogenesis
was assessed by alizarin red staining. For evaluation of the
mineralized matrix, induced EMF-iPSCs were treated with 2%
silver nitrate (Sigma) under UV radiation for 1 h. Cells were
fixed with 2.5% sodium thiosulfate (Sigma) for 5 min and
washed in dH2O. Cells were then counterstained with 1%
neutral red (Sigma) for 1 min [14].Neurogenic differentiation
First, 1  105 EMF-iPSCs at the 5th to 8th -passage were
treated with serum-free modified neurogenic selection medium
for two weeks. The serum-free medium for the selection of
neural precursor cells contained DMEM/F12 1:1 (Gibco/BRL)
and was supplemented with 0.6% glucose, 25 mg/ml insulin,
100 mg/ml transferrin, 20 nM progesterone, 60 mM putrescine,
30 nM selenium chloride, 2 mM glutamine, 3 mM sodium
bicarbonate, 5 mM HEPES, 2 mg/ml heparin, 20 ng/ml EGF,
and 20 ng/ml bFGF (all from Sigma, St. Louis, MO). For
further neural differentiation, EGF was removed from the
medium, and the medium was supplemented with 20 ng/ml
SHH (R&D), 10 ng/ml BDNF (R&D), and all-trans retinoic
acid (100 nM) for another seven days [21].Karyotypic analysisTo assess whether EMFs (n ¼ 3) and EMF-iPSCs (n ¼ 3)
maintain a normal karyotype, passage ten cells were harvested
at 70e80% confluency and resuspended in 10 mL of colcemid
per mL of media. Cells were incubated at 37C for 3e6 h,
after which cells were resuspended in 0.5 mL of medium and
mixed with 0.075 M KCl to a volume of 10 mL. After incu-
bation for 10e15 min at 37C in a waterbath, cells were
resuspended in a total of 10 mL of fixative (methanol:acetic
acid ratio: 3:1). Staining with DAPI for G-banding was per-
formed by equilibrating the slides in 0.3 M sodium citrate,
which contained 3 M NaCl, for 5 min and subsequently
adding two drops of Antifade with DAPI per slide before
visualization [15].
Results
Among the adult somatic cells, the human endometrium
displays unique features with regard to regenerative potential
and plasticity, rendering it an excellent candidate for reprog-
ramming into the pluripotent state. Therefore, human EMFs are
thought to be amenable to reprogramming into iPSCs. To gain
further insight into the possibility that human EMF are a candi-
date for iPSCs generation, we followed the approach of Yama-
naka’s group by introducing four factors in the isolated human
EMFs [1,19]. Culture-expanded fibroblasts that are derived
from EMFs differentially adopt mesodermal lineages [22]. To
improve the pluripotent and multi-lineage differentiation abili-
ties, EMF (Fig. 1A upper left) introduced with OSKM were
reprogrammed into EMF-iPSCs (Fig. 1A upper right). Undif-
ferentiated iPSCs were cultured on inactivated MEFs and
formed colonies highly similar to human ESCs (H9) (Fig. 1A,
upper right). EMF-iPSCs formed 3D spheroid bodies at day 14
(Fig. 1A, lower left). These iPSC clones were positively stained
for alkaline phosphatase (Fig. 1A, lower right), Oct-4, and
SSEA-1 (data not shown). We used a quantitative PCR analysis
to examine whether stem cell markers were expressed in EMF-
iPSCs introduced with OSKM (OSKM-iPSCs) and H9. Mild
expression of endogenous Klf4 was detected in endometrium
whereas strong expression of all stem cell markers was detected
in both OSKM-iPSCs and H9 (Fig. 1B).
Fig 1. Characterization of endometrial fibroblasts (EMFs) and inducible pluripotent stem cells (iPSCs) derived from EMF (EMF-iPSCs). (A) Morphology of EMF
isolated from tissue samples of normal endometrium. EMF-iPSCs developed a cluster-like morphology, and cell aggregates were observed at day 7. EMF-iPSCs
formed 3D spheroid-bodies (SB-EMF-iPSCs) at day 14. Reprogramming plates stained with alkaline phosphate and relative reprogramming efficiencies of EMF-
iPSCs. Bars: 50 mm. (B) Representative quantitative PCR analysis of EMFs and reprogrammed iPSCs for markers of pluripotency and reprogramming factors
relative to factor levels in human embryonic stem cells (hESCs) (H9). Input EMFs express very low levels of most factors whereas EMF-iPSCs display levels
similar to hESCs (H9).
38 Y.-J. Chen et al. / Taiwanese Journal of Obstetrics & Gynecology 51 (2012) 35e42
Fig 2. Karyotyping study. (A) Karyotype analysis of endometrial fibroblasts (EMFs) and (B) EMF-inducible pluripotent stem cells show normal karyotypes of
46, XX.
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to expand without acquiring carcinogenic potential; to be
useful, the cells must maintain a normal karyotype. Fig. 2A
shows that EMFs have 23 pairs of chromosomes with noaneuploidy or other abnormalities, even after five cell passages.
Even after EMFs introduced with OSKM were reprogrammed
into EMF-iPSCs, there was no difference between EMFs and
EMF-iPSCs in the karyotypic analysis (Fig. 2B).
Fig 3. Potential for adipogenic, osteogenic and neuronal differentiation in
endometrial fibroblast (EMF)-inducible pluripotent stem cells (iPSCs), but not
in EMFs. (A) After 14 days of adipogenic induction, EMF-iPSCs were able to
differentiate into adipocytes with positive oil-red O staining (an adipogenic
gene). (B) Phase contrast imaging of the EMF inducible pluripotent stem-
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differentiation from EMF-iPSCsEMF-iPSCs have the capacity to differentiate in both
mesodermal (osteocyte and adipocyte) and ectodermal (neuron)
tissue lineages (Fig. 3), but EMF do not. These results are
detailed below.
EMF-iPSCs successfully differentiated into adipocytes in
14 days when treated with adipogenic medium. These cells
were positive for oil-red O staining (Fig. 3A). NPCs were
generated from OSKM-EMF-iPSCs by employing the protocol
of neurogenic differentiation. After 14 days, neuron-like cells
with neurite formation were observed (Fig. 3B). To test the
potential for osteogenic differentiation of EMF-iPSCs, fifth-
passage cells were cultured in the presence of a high
concentration of dexamethasone and b-glycerophosphate.
These cells exhibited osteocyte phenotypes as evidenced by
alizarin red staining (Fig. 3C). These results suggest that the
EMF-iPSCs could be reprogrammed from EMF cells. There-
fore, endometrial tissues and endometrium-derived cells could
be an alternative source of cells that can produce iPSCs with
cell reprogramming.
Discussion
Our results demonstrate that the endometrium could be
a source of stem cells or fibroblasts to induce iPSCs. During the
menstrual cycle, the endometrium undergoes periodic and
dramatic changes involving tissue loss and regeneration. After
menstruation, the stratum functionalis regenerates from the
stratum basalis during the proliferative phase, reaching
a thickness of up to 5e6 mm at the peak of the secretory phase.
In the absence of implantation, the functionalis layer is shed,
leaving the basalis, which is a structurally stable compartment
of the uterus that is not degraded during menstruation [23]. In
addition to its plasticity and regenerative capacity, the endo-
metrium is also an easily accessible source of abundant cells
that can be obtained through biopsy using minimally invasive
techniques; additionally, the cells are easy to maintain and
propagate in vitro with standard laboratory techniques [24].
Recently, Yamanaka and colleagues [1,19] demonstrated that
induced iPSCs could be generated from MEFs as well as from
adult human fibroblasts via the retrovirus-mediated trans-
fection of four transcription factors, namely, Oct-3/4, Sox2,
c-Myc, and Klf4. These studies further suggest that iPSCs are
indistinguishable from ESCs with respect to morphology,
proliferative abilities, surface antigens, gene expressions,
epigenetic status of pluripotent cell-specific genes, and telo-
merase activity. In this study, we successfully isolated EMF
cells from human endometrial tissues and reprogrammed the
EMFs into EMF-iPSCs. The quantitative PCR results show that
EMF-iPSCs preserved the genetic characteristics of a primitive
embryonic stage as evidenced by the expression of the genesderived neuron-like cells. (C) Following 14 days of osteogenic differentia-
tion, EMF-iPSCs differentiated into osteocyte-like cells, as detected by ali-
zarine red staining. Bars: 50 mm.
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iPSCs have 23 pairs of chromosomes with no aneuploidy or
other abnormalities. Moreover, as compared with EMFs, EMF-
iPSCs can efficiently differentiate into adipogenic, osteogenic,
and neuronal cells. Our results suggest that the EMF-iPSCs can
be reprogrammed from EMFs.
Recently, Park et al. [16] showed that iPSCs could also be
generated and reprogrammed from the endometrial cells that
were transduced with Oct-4, Sox2, Klf4, and Myc [16].
Accordingly, the time for the derived iPSCs to be subcultured
and propagated was 12 days, which is significantly earlier than
the iPSCs derived from other cell types [16]. Moreover, the
colony-forming efficiency of the endometrial cell-derived
iPSCs was also higher than the skin fibroblast-derived
iPSCs, indicating that endometrial cells are more efficient
sources for human iPSC generation [16]. According to the
report of Park et al [16], the embryonic bodies of the iPSCs
derived from the endometrial cells expressed high levels of the
markers for endoderm (e.g., AFP and GATA4), mesoderm
(e.g., RUNX1 and brachyury) and ectoderm (e.g., nestin and
NCAM1) than the endometrial iPSCs of origin [16]. In our
study, we further found that EMF-iPSCs could be differentiated
into neuronal-like cells, adipocytes and osteocyte-like cells,
indicating that these EMF-iPSCs also have the potential for
multi-lineage differentiation (Fig. 3) with intact genomes that
were not interrupted by exogenous retroviral transduction
(Fig. 2). Because of the physiological characteristics of the
endometrium, which exhibit periodic macroscopic and micro-
scopic tissue loss, regeneration, and differentiation, both our
results and those from Park et al [16] suggest that the endome-
trium might be a good candidate source for iPSCs generation.
The advantages of iPSCs over ESCs are that iPSCs can be
derived from the patient’s somatic cells, thus avoiding the
potential for immune rejection, and that they avoid the ethical
concerns associated with ESCs. For example, a recent study
demonstrated that patient-specific iPSCs from dermal fibro-
blasts of patients with long-QT syndrome can differentiate into
functional cardiac myocytes but recapitulated the electro-
physiological features of the disorder [8]. Safe iPSC clone-
derived neural stem cell/NPCs could be an important source
for transplantation therapy in stroke and neurodegenerative
diseases [9,25]. The use of L-Myc to replace c-Myc, combined
with Oct-4/Sox2/Klf4, promotes iPSCs generation without
tumor formation [26]. We previously showed that the subdural
transplantation of iPSCs mixed with fibrin glue did not result
in tumor formation after 6 weeks [11]. Therefore, the major
advantage of iPSCs over ESCs is that iPSCs can be derived
from a patient’s own somatic cells, they can be used for
autologous transplantation without the risk of rejection, they
avoid the ethical concerns associated with using ESCs, and
they are regarded as candidates for cell therapy [1e4].
Among the four factors for conventional iPSCs reprogram-
ming, the pro-oncogene c-Myc has a critical role in influencing
reprogramming efficiency [10,26]. However, a previous report
suggested that deregulated expression of c-Myc occurs in a wide
range of human cancers; it is often associated with poor prog-
nosis and may contribute to tumorigenesis by over-stimulatingcell growth and metabolism and/or by causing genomic insta-
bility [27]. Thus, this oncogene may have a key role in tumor
progression [27]. Therefore, the introduction of c-Myc could be
a major obstacle in iPSC-based cell transplantation because of
the tumorigenetic propensity and the risk of teratoma formation
in vivo [11]. To eliminate teratoma formation, some alternative
experimental approaches have been employed in several studies.
One recent study demonstrated that replacing c-Mycwith L-Myc
in combination with Oct-4, Sox2, and Klf4 promoted iPSC
generation without tumor formation [26]. Tsuji et al [9]
demonstrated that transplantation of neurospheres derived
from safe iPSC clones into injured spinal cords promoted
a functional recovery without any teratoma formation [9]. In one
of our recent studies, we demonstrated that the oncogene c-Myc
was expected to substantially contribute to tumor formation in
acute hepatic failure (AHF) recipients but that the tumor
formation could be prevented in the livers of mice that received
3-genes iPSCs and 3-genes iPSC-Heps 6 months after trans-
plantation. Although the exclusion of c-Myc resulted in a less
efficient induction of MEFs to iPSCs, we have shown that the 3-
genes iPSC colonies were positive for Oct-4, SSEA-1 (ESC
markers), and alkaline phosphatase, and that they were not
affected by passage number; these results are identical to the
results obtained from 4-genes iPSC colonies. Furthermore, the
microarray gene expression between 3-genes IPSCs, 4-genes
iPSCs, and ESCs were similar, and the 3-genes iPSC-derived
embryonic bodies could also be differentiated into a neuro-
ectodermal lineage (neuron-like cells), mesodermal lineages
(osteocyte-like cells and adipocyte-like cells), and regular-
beating cardiomyocyte-like cells. In addition, this mouse 3-
genes iPSC (Oct-4/Sox2/Klf4) clone formed chimeric
offspring through in vitro fertilization. This molecular, histo-
logical, and differentiation evidence implies a niche for 3-
genes iPSCs in future cell therapy and demonstrates that
iPSCs without c-Myc, especially under differentiated states, is
a more feasible cell source for iPSC-based replacement
therapy and in vitro screening.
In this study, the EMFs were reprogrammed into iPSCs
through the cell reprogramming process by the introduction of
four transcription factors. The sort of approach that employs the
production of induced pluripotency as an intermediate for cell
lineage switch is based on the landmark development of
Takahashi and Yamanaka. Although several issues have been
elucidated, such as the similarity between iPSCs and ESCs and
the mechanism underlying the reprogramming of somatic cells
to iPSCs, concerns regarding low reprogramming efficiency and
the optimal strategy for pre-defined factor delivery remain to be
clarified. Furthermore, the approach by transcription factor-
based technology to induce cell reprogramming and pluri-
potency can be widely used in cell therapy, disease modeling,
personalized medicine, and regenerative medicine [28]. In
addition, several recent studies have shown an direct conversion
from one to another type of cell or lineage and bypass pluri-
potency induction (e.g., from fibroblasts to excitatory neurons
[29], cardiomyocytes [30], myeloid cells, and erythroid cells
[31]). Therefore, both iPSC technology and direct reprogram-
ming technology have the potential to become two important
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[28], and direct reprogramming of adult cells from one lineage
of somatic cells to another combined with non-viral vector
delivery should be further studied.
In conclusion, this is the first study to show that EMFs can
be reprogrammed to iPSCs and that they are able to differ-
entiate into multiple-lineage cells. In contrast to cell trans-
plantation therapies, the application of stem cells can further
provide a platform for drug discovery and small molecular
testing. Therefore, EMFs are an excellent source of adult stem
cells, and this approach to cell replacement therapy should
overcome the ethical and immunologic concerns associated
with the use of fetal tissues and ESCs.
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